- Home
- SCNX vs NCEL Comparison
SCNX vs NCEL Comparison
Compare SCNX & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNX | NCEL |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | Switzerland |
| Employees | 19 | 4 |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 17.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SCNX | NCEL |
|---|---|---|
| Price | $0.36 | $3.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 325.9K | 17.1K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,097.38 | N/A |
| Revenue Next Year | $239.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $1.83 |
| 52 Week High | $2.60 | $5.12 |
Technical Indicators
Market Signals| Indicator | SCNX | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 64.40 |
| Support Level | $0.31 | $2.95 |
| Resistance Level | $0.43 | $4.07 |
| Average True Range (ATR) | 0.04 | 0.25 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 45.24 | 100.00 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.